Literature DB >> 27228991

Diagnostic colonoscopy following a positive fecal occult blood test in community health center patients.

David T Liss1, Tiffany Brown2, Ji Young Lee2, Marjorie Altergott3, David R Buchanan4, Anne Newland5, Jessica N Park6, Sarah S Rittner6, David W Baker2,7.   

Abstract

PURPOSE: Fecal occult blood testing (FOBT) is a pragmatic screening option for many community health centers (CHCs), but FOBT screening programs will not reduce mortality if patients with positive results do not undergo diagnostic colonoscopy (DC). This study was conducted to investigate DC completion among CHC patients.
METHODS: This retrospective cohort study used data from three CHCs in the Midwest and Southwest. The primary study outcome was DC completion within 6 months of positive FOBT among adults age 50-75. Patient data was collected using automated electronic queries. Manual chart reviews were conducted if queries produced no evidence of DC. Poisson regression models described adjusted relative risks (RRs) of DC completion.
RESULTS: The study included 308 patients; 63.3 % were female, 48.7 % were Spanish speakers and 35.7 % were uninsured. Based on combined query and chart review findings, 51.5 % completed DC. Spanish speakers were more likely than English speakers to complete DC [RR 1.19; 95 % confidence interval (CI) 1.04-1.36; P = 0.009], and DC completion was lower among patients with 0 visits than those with 1-2 visits (RR 2.81; 95% CI 1.83-4.33; P < 0.001) or ≥3 visits (RR 3.06; 95% CI 1.57-5.95; P = 0.001).
CONCLUSIONS: DC completion was low overall, which raises concerns about whether FOBT can reduce CRC mortality in practice. Further research is needed to understand whether CHC navigator programs can achieve very high DC rates. If organizations use FOBT as their primary CRC screening approach and a substantial number of patients receive positive results, both screening rates and DC rates should be measured.

Entities:  

Keywords:  Cancer screening; Colorectal cancer; Diagnosis; Disparities; Preventive care

Mesh:

Year:  2016        PMID: 27228991     DOI: 10.1007/s10552-016-0763-0

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  12 in total

1.  Contribution of patient, physician, and environmental factors to demographic and health variation in colonoscopy follow-up for abnormal colorectal cancer screening test results.

Authors:  Melissa R Partin; Amy A Gravely; James F Burgess; David A Haggstrom; Sarah E Lillie; David B Nelson; Sean M Nugent; Aasma Shaukat; Shahnaz Sultan; Louise C Walter; Diana J Burgess
Journal:  Cancer       Date:  2017-05-11       Impact factor: 6.860

2.  Predictors of Colorectal Cancer Screening Prior to Implementation of a Large Pragmatic Trial in Federally Qualified Health Centers.

Authors:  Amanda F Petrik; Thuy Le; Erin Keast; Jennifer Rivelli; Keshia Bigler; Beverly Green; William M Vollmer; Gloria Coronado
Journal:  J Community Health       Date:  2018-02

3.  Patient randomized trial of a targeted navigation program to improve rates of follow-up colonoscopy in community health centers.

Authors:  Gloria D Coronado; Eric S Johnson; Michael C Leo; Jennifer L Schneider; David Smith; Raj Mummadi; Amanda F Petrik; Jamie H Thompson; Ricardo Jimenez
Journal:  Contemp Clin Trials       Date:  2019-12-24       Impact factor: 2.226

4.  Screening for Colorectal Cancer in the United States: Correlates and Time Trends by Type of Test.

Authors:  Jean A Shapiro; Ashwini V Soman; Zahava Berkowitz; Stacey A Fedewa; Susan A Sabatino; Janet S de Moor; Tainya C Clarke; V Paul Doria-Rose; Erica S Breslau; Ahmedin Jemal; Marion R Nadel
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-06-04       Impact factor: 4.090

5.  Mailed fecal immunochemical test outreach for colorectal cancer screening: Summary of a Centers for Disease Control and Prevention-sponsored Summit.

Authors:  Samir Gupta; Gloria D Coronado; Keith Argenbright; Alison T Brenner; Sheila F Castañeda; Jason A Dominitz; Beverly Green; Rachel B Issaka; Theodore R Levin; Daniel S Reuland; Lisa C Richardson; Douglas J Robertson; Amit G Singal; Michael Pignone
Journal:  CA Cancer J Clin       Date:  2020-06-25       Impact factor: 286.130

6.  Demographic and comorbidity predictors of adherence to diagnostic colonoscopy in the Danish Colorectal Cancer Screening Program: a nationwide cross-sectional study.

Authors:  Mette Kielsholm Thomsen; Morten Rasmussen; Sisse Helle Njor; Ellen Margrethe Mikkelsen
Journal:  Clin Epidemiol       Date:  2018-11-23       Impact factor: 4.790

7.  Is the patient activation measure associated with adherence to colonoscopy after a positive fecal occult blood test result?

Authors:  Revital Azulay; Liora Valinsky; Fabienne Hershkowitz; Racheli Magnezi
Journal:  Isr J Health Policy Res       Date:  2018-12-21

8.  Repeated Automated Mobile Text Messaging Reminders for Follow-Up of Positive Fecal Occult Blood Tests: Randomized Controlled Trial.

Authors:  Revital Azulay; Liora Valinsky; Fabienne Hershkowitz; Racheli Magnezi
Journal:  JMIR Mhealth Uhealth       Date:  2019-02-05       Impact factor: 4.773

9.  Prospective Cohort study of Predictors of Follow-Up Diagnostic Colonoscopy from a Pragmatic Trial of FIT Screening.

Authors:  Elizabeth A O'Connor; Carrie M Nielson; Amanda F Petrik; Beverly B Green; Gloria D Coronado
Journal:  Sci Rep       Date:  2020-02-12       Impact factor: 4.379

10.  The COVID-19 Pandemic: Identifying Adaptive Solutions for Colorectal Cancer Screening in Underserved Communities.

Authors:  Jesse N Nodora; Samir Gupta; Nicole Howard; Kelly Motadel; Tobe Propst; Javier Rodriguez; James Schultz; Sharon Velasquez; Sheila F Castañeda; Borsika Rabin; María Elena Martínez
Journal:  J Natl Cancer Inst       Date:  2021-08-02       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.